Hologic Inc
HOLX
$76.01
+0.48%
Hologic Inc. is a specialized healthcare company focused on developing and manufacturing proprietary products for women's health, operating primarily in the medical instruments and supplies industry. The company is a market leader in women's diagnostics and breast health, with its competitive identity built on a portfolio of essential screening and diagnostic technologies, including its flagship 3D mammography systems and molecular diagnostic platforms. The current investor narrative is dominated by a transformative event, as recent news headlines indicate the company has agreed to be taken private in an $18 billion acquisition by private equity firms Blackstone and TPG, which is driving significant attention and debate around the stock's final valuation and the strategic rationale behind exiting the public market.…
HOLX
Hologic Inc
$76.01
Related headlines
Investment Opinion: Should I buy HOLX Today?
Rating & Thesis: The recommendation is Hold. The core thesis is that HOLX is a takeover arbitrage play with limited upside and defined, but material, downside risk, making it unsuitable for new capital allocation despite its strong underlying business. The stock is trading at the effective deal price, and analyst coverage/sentiment has been suspended or turned neutral due to the pending transaction.
Supporting Evidence: The stock trades at a forward P/E of 15.64x, which is reasonable but not deeply discounted. Revenue growth is stable but slow at 2.54% YoY. Profitability is solid on a TTM basis with a 13.80% net margin, but quarterly results are inconsistent. Most critically, the stock price of $76.01 is just $0.06 below its 52-week high, implying the market sees minimal gap to the final acquisition valuation, offering negligible implied upside.
Risks & Conditions: The two biggest risks are deal break risk and opportunity cost. This Hold rating would upgrade to a Buy only if the stock price meaningfully discounted the deal (e.g., a 5-10% gap to the implied acquisition price emerged). It would downgrade to a Sell if material negative news surfaced regarding the acquisition's likelihood of closing. Relative to its history and peers, the stock is fairly valued for a company in a pending acquisition, but it is not undervalued for a new investment.
Sign up to view all
HOLX 12-Month Price Forecast
The 12-month outlook is a binary event driven by the acquisition's fate. The high-probability (70%) bull case is the deal closing, offering minimal upside from current levels. The bear case, while low probability (10%), carries a severe -32% downside to the 52-week low. This creates a highly asymmetric risk/reward profile unfavorable for new buyers. The stance is neutral due to the lack of attractive entry points. An upgrade to bullish would require a significant price drop creating an arbitrage spread; a downgrade to bearish would be triggered by concrete signs the deal is in jeopardy.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hologic Inc's 12-month outlook, with a consensus price target around $98.81 and implied upside of +30.0% versus the current price.
Average Target
$98.81
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$61 - $99
Analyst target range
Analyst coverage for HOLX appears limited in the provided data, with only 7 analysts cited for EPS estimates, and no explicit consensus price target, buy/hold/sell distribution, or target range is available in the dataset. This suggests insufficient public analyst coverage to derive a meaningful consensus sentiment or implied upside/downside, a situation that may be attributable to the company's pending acquisition, which typically leads analysts to suspend coverage and price targets. The institutional ratings data shows a clear pattern of downgrades to neutral or hold ratings in late 2025, with firms like JP Morgan, Mizuho, and Raymond James moving from Outperform/Overweight to Neutral/Market Perform, signaling that analysts were turning cautious on the stock's standalone public market prospects prior to the acquisition announcement.
Bulls vs Bears: HOLX Investment Factors
The investment thesis for HOLX is overwhelmingly dominated by the pending $18 billion acquisition, which has created a powerful bull case centered on a risk-capped exit at a premium. The bear case focuses on the company's standalone challenges: modest growth, earnings volatility, and the lack of further upside. Currently, the bull side has stronger evidence, as the deal provides a concrete floor and exit strategy. The single most important tension is deal completion risk versus the certainty of the premium. If the deal closes, shareholders are paid; if it fails, the stock could re-rate sharply lower based on its standalone fundamentals.
Bullish
- Pending Acquisition at Premium: The stock is subject to an $18 billion take-private deal by Blackstone and TPG, announced on April 8, 2026. This event provides a clear exit at a significant premium, with the stock trading just $0.06 below its 52-week high of $76.07, effectively capping downside risk.
- Strong Financial Health & Cash Flow: The company generates robust free cash flow of ~$1.0 billion TTM and maintains a strong balance sheet with a current ratio of 3.75 and a manageable debt-to-equity of 0.52. This financial stability made it an attractive target for private equity.
- Market Leadership in Niche: Hologic is a leader in women's health diagnostics and breast health, with its diagnostics (44% of sales) and breast health (38%) segments providing stable, essential revenue streams. This defensive market position supports consistent profitability, evidenced by a TTM net margin of 13.80%.
- Attractive Forward Valuation: The forward P/E ratio of 15.64x is significantly lower than the trailing P/E of 26.99x. This forward multiple is reasonable for a profitable healthcare company and likely reflects the acquisition price, limiting valuation risk for current holders.
Bearish
- Stagnant Standalone Growth: Recent quarterly revenue growth is anemic at 2.54% YoY, and the business has shown volatility, with a revenue dip to $1.01B in Q2 2025. This lack of robust organic growth likely contributed to the decision to sell.
- Inconsistent Quarterly Profitability: While profitable overall, the company posted a net loss of -$17.4 million in Q2 2025, and gross margin fluctuated from a low of 37.5% to a high of 60.9% over recent quarters. This earnings volatility complicates standalone valuation.
- Analyst Downgrades Pre-Deal: Prior to the acquisition news, several major firms (JP Morgan, Mizuho, Raymond James) downgraded HOLX to Neutral/Hold in late 2025. This indicates waning confidence in the stock's public market prospects as a standalone entity.
- Limited Upside to Deal Price: Trading at $76.01, the stock is essentially at its 52-week high with a 1-year return of 24.89%. With the acquisition price implied by the current trading level, there is minimal room for further capital appreciation, offering a near-zero expected return from here.
HOLX Technical Analysis
The stock is in a sustained uptrend, evidenced by a 1-year price change of +24.89%, and is currently trading at the very top of its 52-week range, with a price of $76.01 just $0.06 below the 52-week high of $76.07. This positioning near all-time highs reflects strong momentum but also suggests the stock is fully valued on a technical basis, with limited immediate upside before the announced acquisition. Recent momentum has been positive but decelerating, with a 3-month gain of +1.47% and a 1-month gain of +0.36%, indicating consolidation at elevated levels as the market digests the takeover news; this short-term trend is consistent with the longer-term uptrend but shows a loss of acceleration. Key technical support is at the 52-week low of $51.90, while immediate resistance is the 52-week high of $76.07; a definitive breakout above this level seems constrained by the acquisition price, while a breakdown is unlikely given the deal premium. The stock's beta of 0.703 indicates it is approximately 30% less volatile than the broader market (SPY), which is typical for a mature healthcare company and suggests it has been a lower-risk holding during its ascent.
Beta
0.70
0.70x market volatility
Max Drawdown
-19.6%
Largest decline past year
52-Week Range
$52-$76
Price range past year
Annual Return
+24.9%
Cumulative gain past year
| Period | HOLX Return | S&P 500 |
|---|---|---|
| 1m | +0.4% | +2.6% |
| 3m | +1.5% | -2.3% |
| 6m | +11.2% | +2.6% |
| 1y | +24.9% | +27.3% |
| ytd | +1.9% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HOLX Fundamental Analysis
Revenue growth is stable but modest, with the most recent quarterly revenue of $1.05 billion representing a year-over-year growth of 2.54%; however, the multi-quarter trend shows volatility, with revenue dipping to $1.01 billion in Q2 2025 before recovering, indicating underlying business stability but not robust expansion. The company is solidly profitable, with net income of $179.1 million in the latest quarter and a gross margin of 55.96%; profitability has been inconsistent quarter-to-quarter, as seen in a net loss of -$17.4 million in Q2 2025, but the trailing twelve-month net margin of 13.80% and operating margin of 17.42% demonstrate overall healthy earnings power. The balance sheet and cash flow are strong, with a robust current ratio of 3.75, a manageable debt-to-equity ratio of 0.52, and substantial free cash flow generation of approximately $1.0 billion TTM; this financial health, characterized by high liquidity and strong cash conversion, provides significant flexibility and was likely a key attraction for the private equity acquirers.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$999599999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HOLX Overvalued?
Given the company's consistent profitability (Net Income > 0), the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 26.99x, while the forward PE is notably lower at 15.64x, indicating the market expects significant earnings growth or, more pertinently, that the forward multiple reflects the acquisition price. Compared to sector averages, the trailing PE of 26.99x is elevated relative to typical medical device peers, suggesting a premium valuation that is likely justified by the company's strong market position, cash flow generation, and the strategic control premium embedded in the buyout offer. Historically, the stock's own PE ratio has fluctuated significantly, from a low near -198x during a loss-making quarter to highs above 46x; the current trailing PE of 26.99x sits above the median of its recent historical range, which aligns with the stock trading near its 52-week high in anticipation of the acquisition closing.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -199x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is earnings volatility, as demonstrated by the swing from a $194.9M net income in Q3 2025 to a -$17.4M loss in Q2 2025. Gross margin compression is a key driver, having fallen to 37.5% in that loss-making quarter. While the balance sheet is strong (D/E 0.52), revenue concentration in the cyclical diagnostics segment (44% of sales) and dependence on the U.S. market (69% of sales) expose the business to regional healthcare spending fluctuations. The modest 2.54% YoY revenue growth suggests limited organic expansion levers.
Market & Competitive Risks: The paramount market risk is the acquisition failing to close. If the deal breaks, the stock's elevated trailing P/E of 26.99x (a premium to many medical device peers) would be vulnerable to severe compression as it re-prices on standalone fundamentals. The stock's low beta of 0.703 indicates it is not highly sensitive to broad market swings, but it remains exposed to sector-specific regulatory headwinds in women's health and diagnostics. Competitive disruption from AI-driven diagnostics, as highlighted by RadNet's recent acquisition of Gleamer, represents a longer-term threat to Hologic's core markets.
Worst-Case Scenario: The worst-case scenario is the announced acquisition collapsing due to regulatory rejection, financing issues, or a material adverse change at Hologic. In this event, the stock would likely plummet to re-price based on its standalone value. A realistic downside target would be the 52-week low of $51.90, representing a potential loss of approximately -32% from the current price of $76.01. The historical max drawdown of -19.64% is less severe, but a deal break would likely exceed that, driven by the evaporation of the control premium and a return to analyst skepticism evidenced by pre-deal downgrades.
FAQ
The key risks are: 1) Deal Completion Risk: The acquisition could fail due to regulatory, financing, or MAC issues, potentially causing a -32% drop. 2) Opportunity Cost: Capital is tied up with near-zero expected return while awaiting a closing that could take months. 3) Fundamental Volatility: As a standalone company, HOLX has shown inconsistent profitability (e.g., a net loss in Q2 2025) and gross margin fluctuations. 4) Sector Competition: Long-term, the rise of AI in diagnostics (as seen with RadNet's Gleamer buy) could pressure Hologic's market leadership. Deal break risk is the most severe and immediate.
The forecast is bifurcated by the acquisition outcome. The base forecast (70% probability) is for the stock to trade between $76.01 and $76.07 until the deal closes, providing no meaningful return. The bear case (10% probability) forecasts a drop to a range of $51.90 to $60.00 if the deal breaks. A delayed-closing scenario (20% probability) could see the stock trade between $65.00 and $70.00. The most likely scenario is the deal closing as planned, but this is already fully priced in, making the forecast for price appreciation flat.
HOLX is fairly valued in the context of the acquisition. Its trailing P/E of 26.99x appears elevated for the medical devices sector, but this incorporates a control premium. The more relevant forward P/E of 15.64x is reasonable and reflects the takeover price. Compared to its own historical range, the stock is trading at the high end, justified by the pending transaction. The valuation implies the market is paying a fair price for the certainty of the deal closing, not for the company's standalone growth prospects, which are modest at 2.54% YoY revenue growth.
For new investors, HOLX is not a good stock to buy at its current price of $76.01. The stock is trading at the effective ceiling set by the pending $18 billion acquisition, offering minimal expected upside. The potential downside in a deal-break scenario is significant, approximately -32% to the 52-week low of $51.90. It may only be a good buy for very specialized arbitrageurs if a meaningful discount to the deal price emerges, which is not currently the case. Existing shareholders are best advised to hold for deal completion.
HOLX is suitable only for a short-term, event-driven investment horizon tied directly to the acquisition timeline. The investment thesis evaporates once the deal closes and the company goes private. Given the stock's low beta of 0.70, it is not a high-volatility trading vehicle, but its fate is binary. The suggested minimum holding period is until the deal closes, which could be 6-12 months. It is categorically unsuitable as a long-term holding, as it will cease to be a public company post-acquisition.